ArticleArchives of microbiology2026
Multi-omics characterization of Saccharomyces boulardii in the biocontrol of Aspergillus flavus.
Article in Archives of microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aspergillus flavus pose a major threat due to aflatoxin contamination to the crops and is commonly controlled through chemical fungicides. However, these treatments raise serious concerns regarding environmental sustainability and human health, underscoring the pressing need for safer and more sustainable alternatives. This study investigates the Saccharomyces boulardii mediated inhibition of Aspergillus flavus using integrated proteomic and metabolomic approach. The activity of S. boulardii extract was assessed by the MTT assay, which demonstrated significant inhibition of A. flavus conidia with an MIC₅₀ of 1.57 mg/mL. Co-cultures of S. boulardii and A. flavus at ratios of 1:1, 10:1, and 20:1 were monitored from day 1 to day 6. A clear inhibition of A. flavus was observed at the 20:1 ratio. To understand the mechanism of inhibition, the proteomic analysis using nLC-ESI-MS/MS at 7 and 24 h (20:1, S. boulardii: A. flavus) identified 2,247 proteins and 2,142, respectively. From 2094 commonly expressed proteins, 782 were differentially expressed proteins (at 2-fold change); including 646 upregulated and 112 were downregulated proteins from S. boulardii, while upregulated and 6 downregulated proteins from A. flavus. The predominance of S. boulardii proteins indicates higher metabolic activity, particularly in pathways related to lipid, amino acids, and nutrient metabolism, whereas downregulation of A. flavus proteins involved in signaling and glucose metabolism suggests impaired energy production and stress response. Using LC/MS, metabolomic analysis of 20:1 co-culture at 24 h showed 16 metabolites linked to antimicrobial and antioxidant activities compared to metabolites from monoculture of A. flavus and S. boulardii. In addition, the co-culture extract exhibited significantly higher antioxidant activity (80%) compared to S. boulardii monoculture (22%). These findings highlight S. boulardii as a biocontrol agent against A. flavus, mediated through growth inhibition and metabolic interference.
Indexed as
Identifiers
42560506What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.